Drug Purchases’s analysis for COVID-19 treatment in Rio Grande do Sul
DOI:
https://doi.org/10.30968/rbfhss.2021.122.0554Abstract
Objective: To evaluate quantities and costs of drug purchases related to COVID-19 treatment by regional governments under the Tribunal de Contas do Estado do Rio Grande do Sul (TCE-RS). Methods: A cross sectional study whose data collection was carried out in accordance with the data registered in the LicitaCon system of TCE-RS until September 29, 2020. The purchase processes of the pharmaceutical products hydroxychloroquine, chloroquine, ivermectin, nitazoxanide, vitamin D, vitamin C and zinc were analyzed in more detail. Results: There were 5,299 purchase processes registered on LicitaCon. Two hundred and fifty cases contained medications, of which 232 were analyzed, for only these met the study’s inclusion criteria. At least one of the aforementioned pharmaceutical products was found in 142 (61.2%) of the analyzed cases. Resulting in a total amount of $ 661.913,52 for the analyzed processes. The most purchased drug was ivermectin, present in 80 of the acquisitions, adding up to $ 241.794,81. The municipality of Garruchos, with an estimated population of 2,886, spent $ 6,858 per inhabitant for the obtainment of ivermectin, consuming a total of $ 19.796,06. Conclusions: The use of such pharmaceutical products for COVID-19 goes against the current available scientific evidence, the recommendations of WHO, the Rational Use of Medicines and Evidence-Based Health.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
